Docetaxel-based chemotherapy trials in androgen-independent prostate cancer: First demonstration of a survival benefit

Intermittent chemotherapy in patients wi

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer : Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel

✍ Tomasz M. Beer; Christopher W. Ryan; Peter M. Venner; Daniel P. Petrylak; Gurkam 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## BACKGROUND. Survival in patients with metastatic, chemotherapy‐naive, androgen‐independent prostate cancer (AIPC) is improved with 10 to 12 cycles of docetaxel‐containing chemotherapy but further management is undefined. In the current study, the authors examined retreatment with th